|
SEPRACOR, the US pharmaceuticals firm, has just opened an Irish office but declined to say whether it intends to commence manufacturing operations. Asked repeatedly by the Sunday Tribune whether it will establish a major subsidiary in Ireland, the publicly-listed firm worth over $6.7bn declined to comment. It is understood that while the formation of the company forms part of an "internal structuring" within Sepracor, the drug firm intends the Irish arm to be an actively trading entity. It has previously donated money to Trinity College in Dublin.
Based in Massachusetts, Sepracor is involved in the research, development and commercialisation of drugs primarily for the treatment of respiratory and central nervous system disorders. It is spending $220m to advertise its Lunesta insomnia treatment in the year to next September. Some analysts believe the firm could post strong profitability in its 2006 figures. In 2005 it recorded sales of $820m and an operating loss of $16.6m. It employs over 2,000 people.
|
YOU ARE HERE: 11 November 2007 / tribune.ie / 2007 / 01 / 07
Terms & Conditions 
